Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Wednesday, April 06, 2016 9:02:45 AM
JERUSALEM, Israel, April 6, 2016 /PRNewswire/ --
Intec Pharma Ltd. (NTEC) (INTP.TA), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the company has been informed that the Korean Intellectual Property Office granted a South Korean patent to the company's patent application for an Accordion Pill containing certain drugs, including the combination Carbidopa and Levodopa. The patent, granted under No. 10-1601649, is titled "Carbidopa / Levodopa Gastroretentive Drug Delivery," and is currently scheduled to remain in force until April 17, 2029. The patent belongs to the company's IN-7 patent family, which pertains to the combination of certain drugs with the Accordion Pill.
Zeev Weiss, CEO of Intec Pharma, said: "The approval of this new South Korean patent is an important step for our company in extending the intellectual property protection, and potential future market, for our leading product candidate, the Accordion Pill Carbidopa/Levodopa, beyond the U.S., South Africa and Israel."
Recent INDP News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/12/2024 08:45:11 PM
- Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses • GlobeNewswire Inc. • 09/05/2024 12:30:00 PM
- Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 12:00:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 08/22/2024 02:06:25 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/12/2024 12:16:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 12:01:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:00:28 PM
- Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/12/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 12:00:34 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/07/2024 09:28:25 PM
- Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/06/2024 09:23:56 PM
- Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit • GlobeNewswire Inc. • 06/11/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:30:38 PM
- Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference • GlobeNewswire Inc. • 06/04/2024 12:00:00 PM
- Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20 • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 12:00:18 PM
- Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors • GlobeNewswire Inc. • 05/22/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 12:06:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 12:05:19 PM
- Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/08/2024 12:00:00 PM
- Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM